We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Stryker (SYK) Pull an Earnings Surprise this Season?
Read MoreHide Full Article
Stryker Corporation (SYK - Free Report) is set to report its second-quarter 2016 earnings results on Jul 21. Last quarter, the company reported earnings of $1.24 per share, which beat the Zacks Consensus Estimate by four cents (3.3%).
Notably, Stryker posted a positive earnings surprise of 2.04% on average over the last four quarters.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Stryker’s expanding product portfolio is the key catalyst. We believe that strong growth momentum at the Trauma & Extremities, Spine and Neurotechnology businesses will drive top-line growth.
Additionally, growing adoption of MAKO will drive sales in the orthopedic and reconstructive surgery market. Further, contract wins from large hospitals in the foot and ankle business present considerable growth opportunity. Moreover, frequent acquisitions will improve the company's competitive position.
For the second quarter of 2016, Stryker expects adjusted earnings in the range of $1.33 to $1.38 per share. Unfavorable foreign exchange rate is expected to impact earnings by 3 cents. Moreover, pricing pressure will continue to hurt sales at least in the near term.
Earnings Whispers
Our proven model does not conclusively show that Stryker is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Stryker has a Zacks ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at $1.36.
Zacks Rank: Stryker has a Zacks Rank #3 which increases the predictive power of ESP; but when combined with a 0.00% ESP, it makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our proven model shows they have the right combination of elements to post an earnings beat this quarter:
Gilead Sciences Inc. (GILD - Free Report) with earnings ESP of +6.91% and a Zacks Rank #2.
C.R. Bard Inc. with earnings ESP of +0.41% and a Zacks Rank #2.
The Cooper Companies (COO - Free Report) with earnings ESP of +2.64% and a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Stryker (SYK) Pull an Earnings Surprise this Season?
Stryker Corporation (SYK - Free Report) is set to report its second-quarter 2016 earnings results on Jul 21. Last quarter, the company reported earnings of $1.24 per share, which beat the Zacks Consensus Estimate by four cents (3.3%).
Notably, Stryker posted a positive earnings surprise of 2.04% on average over the last four quarters.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Stryker’s expanding product portfolio is the key catalyst. We believe that strong growth momentum at the Trauma & Extremities, Spine and Neurotechnology businesses will drive top-line growth.
STRYKER CORP Price and EPS Surprise
STRYKER CORP Price and EPS Surprise | STRYKER CORP Quote
Additionally, growing adoption of MAKO will drive sales in the orthopedic and reconstructive surgery market. Further, contract wins from large hospitals in the foot and ankle business present considerable growth opportunity. Moreover, frequent acquisitions will improve the company's competitive position.
For the second quarter of 2016, Stryker expects adjusted earnings in the range of $1.33 to $1.38 per share. Unfavorable foreign exchange rate is expected to impact earnings by 3 cents. Moreover, pricing pressure will continue to hurt sales at least in the near term.
Earnings Whispers
Our proven model does not conclusively show that Stryker is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Stryker has a Zacks ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at $1.36.
Zacks Rank: Stryker has a Zacks Rank #3 which increases the predictive power of ESP; but when combined with a 0.00% ESP, it makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our proven model shows they have the right combination of elements to post an earnings beat this quarter:
Gilead Sciences Inc. (GILD - Free Report) with earnings ESP of +6.91% and a Zacks Rank #2.
C.R. Bard Inc. with earnings ESP of +0.41% and a Zacks Rank #2.
The Cooper Companies (COO - Free Report) with earnings ESP of +2.64% and a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>